Milameline
![]() | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| ECHA InfoCard | 100.220.595 |
| Chemical and physical data | |
| Formula | C8H14N2O |
| Molar mass | 154.213 g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
Milameline (CI-979, PD-129,409, RU-35,926) is a non-selective muscarinic acetylcholine receptor partial agonist with cognition-acting properties that was being investigated for the treatment of Alzheimer's disease, but produced poor results in clinical trials and was subsequently discontinued.[1]
- Changing the O-methyl aldoxime to an O-propargyl oxime instead gives a separate molecule called RU 35986.[2]
See also
References
- ↑ Sedman AJ, Bockbrader H, Schwarz RD (1995). "Preclinical and phase 1 clinical characterization of CI-979/RU35926, a novel muscarinic agonist for the treatment of Alzheimer's disease". Life Sciences. 56 (11–12): 877–82. doi:10.1016/0024-3205(95)00023-Y. PMID 10188788.
- ↑ Broadley, Kenneth J.; Kelly, David R. (2001). "Muscarinic Receptor Agonists and Antagonists". Molecules. 6 (3): 142–193. doi:10.3390/60300142. ISSN 1420-3049. PMC 6236374.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.
